Perrigo reported second-quarter adjusted diluted earnings per share of $1.22 on net sales of $1.2 billion.
The company said it now expects 2017 reported diluted EPS to be in the range of of $0.84 to $1.09, from $1.82 to $2.17 previously. It raised its adjusted EPS outlook to the $4.45 to $4.70 range, from $4.15 to $4.50.
Meanwhile, shares of Portola Pharmaceuticals Inc. (PTLA - Get Report) were down 8.5% to $55.23. The South San Francisco, Calif.-based firm after the market close on Wednesday reported a second-quarter net loss of $69.7 million, or $1.22 per share, compared with a net loss of $57.3 million, or $1.02 per share, in the same period last year.
Portola said collaboration and license revenue earned under its collaboration and license agreements with Bristol-Myers Squibb Co. (BMY - Get Report) and Pfizer Inc. (PFE - Get Report) , Bayer Pharma, Janssen Pharmaceuticals and Daiichi Sankyo was $3.8 million for the quarter, compared with $4.2 million in the year-ago period.
Among the other stock movers was Organovo Holdings Inc. (ONVO - Get Report) , up 6.3% to $2.21. The San Diego company after the market close on Wednesday reported a fiscal first-quarter 2018 net loss of $10.1 million, or $0.10 per share, compared with $8.8 million, or $0.09 per share, in the year-ago period. Revenue rose 11% to $1 million.
The company also affirmed its previously issued full-year fiscal 2018 revenue guidance of between $6 million and $8.5 million, and negative adjusted Ebitda guidance of between $29 million and $31 million.
More of What's Trending on TheStreet: